ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Approach to the male with infertility

Approach to the male with infertility
Literature review current through: Jan 2024.
This topic last updated: Oct 04, 2022.

INTRODUCTION — Infertility in a couple is usually defined as the inability to achieve conception despite one year of regular, unprotected intercourse. When the female partner is >35 years old, infertility is defined as failure to conceive within six months of unprotected intercourse [1]. However, up to 40 to 50 percent of young, healthy couples that fail to conceive in the first 12 months will conceive in the subsequent 12 months with no specific treatment [2,3]. Therefore, in some circumstances, delay in extensive evaluation and treatment is reasonable. In approximately 35 percent of couples with infertility, a male factor is identified along with a female factor; in approximately 10 percent, a male factor is the only identifiable cause.

While many men with male infertility have oligozoospermia (a low number of sperm cells in the ejaculate compared with reference ranges) or azoospermia (no sperm cells in the ejaculate), some infertile men have normal sperm counts. Over 80 percent of infertile men have low sperm concentrations and poor sperm quality (a decrease in sperm motility [asthenozoospermia] and/or an increase in spermatozoa with abnormal morphology [teratozoospermia]). A small percentage of infertile men have normal sperm concentrations but poor sperm quality, and another small percentage of infertile men have normal sperm concentrations and normal motility and morphology.

This topic will review the evaluation of male infertility. The causes and management of male infertility and an overview of infertility are reviewed separately. (See "Causes of male infertility" and "Treatments for male infertility".)

CATEGORIES OF MALE INFERTILITY — The causes of male infertility can be divided into four main areas (table 1) (see "Causes of male infertility"):

Endocrine and systemic disorders with hypogonadotropic hypogonadism – 5 to 15 percent.

Primary testicular defects in spermatogenesis – 70 to 80 percent. Klinefelter syndrome is the most common identifiable cause of a primary testicular defect, but the majority (90 to 95 percent) in this category have idiopathic dysspermatogenesis, an isolated defect in spermatogenesis without an identifiable cause.

Sperm transport disorders – 2 to 5 percent.

Idiopathic male infertility – 10 to 20 percent. Idiopathic male infertility should be distinguished from idiopathic dysspermatogenesis. Idiopathic male infertility describes an infertile man with a normal semen analysis and no apparent cause for infertility, whereas infertile men with idiopathic dysspermatogenesis have abnormal semen analyses.

The precise epidemiology of prevalence and causes of male infertility has never been accurately assessed for several reasons, including differences in definitions of infertility, underreporting, and lack of systematic data gathering [4,5]. The above prevalences are estimations of the proportion of men presenting for infertility treatment at a referral center and likely do not represent the prevalence in the broader community in industrialized countries, nor do these estimations reflect likely regional variations around the world [4-6].

DIAGNOSTIC APPROACH — The initial evaluation of the male with infertility is focused on detecting the small percentage of causes that can be treated to restore normal fertility. The remainder of the evaluation of male infertility is focused on determining which couples with male factor infertility might benefit from assisted reproductive technologies (ART).

Molecular biology techniques have increased the ability to identify more genetic causes of male infertility, but only a minority of infertile men have an identifiable cause (see "Causes of male infertility"). The disorders in many infertile men are characterized primarily by descriptions of observed abnormalities, such as decreased sperm number, movement, or egg-penetrating and fusion capabilities. Even testicular biopsies rarely shed insight on the underlying etiology; they simply indicate the extent of spermatogenic impairment.

The essential components of the evaluation of the infertile man include (see 'Initial visit' below):

History

Physical examination

Semen analysis; if abnormal, it should be repeated

Additional components of the evaluation of the infertile man may include (see 'Additional evaluation' below):

Endocrine testing

Imaging of accessory glands and ducts

Genetic tests

The profile created by the results permits a systematic assessment of the male partner.

Initial visit

History and physical examination — The evaluation of an infertile man should begin with a detailed history that focuses on potential causes of infertility. A detailed history of the female partner should also be obtained, including menstrual history, history of previous fertility (or infertility), and any prior evaluation or treatment of infertility. For the male partner, the clinician should inquire about symptoms, prior illnesses, trauma, surgical procedures, or exposure to testicular toxins that are associated with male hypogonadism (dysspermatogenesis with or without decreased testosterone production):

Sexual developmental history, including testicular descent, pubertal development, loss of body hair, or decrease in shaving frequency.

Chronic severe systemic illness or history of major head trauma, surgery, or irradiation that could result in hypogonadotropic hypogonadism. (See "Causes of secondary hypogonadism in males".)

Infections, such as mumps orchitis, sinopulmonary symptoms, sexually transmitted infections, and genitourinary tract infections (including prostatitis).

Surgical procedures or significant trauma involving the pelvis and genital area.

Drugs and environmental exposures that can adversely impact the hypothalamic-pituitary-testicular axis, including alcohol, tobacco, marijuana, opioids, radiation therapy, anabolic steroids, corticosteroids, cytotoxic chemotherapy (current or past), drugs that cause hyperprolactinemia, and exposure to toxic chemicals (eg, pesticides). (See "Causes of secondary hypogonadism in males".)

Sexual history, including libido, frequency of intercourse, and previous fertility assessments of the man and his partner.

The physical examination should include a general medical examination to determine overall health, obesity, and overt signs of endocrinopathies that are uncommon causes of male infertility (eg, thyroid dysfunction or Cushing's syndrome).

Because some infertile men have combined defects in testosterone and sperm production, the examination should also focus on findings suggestive of androgen deficiency. The clinical manifestations of androgen deficiency depend upon the age of onset. Androgen deficiency during early gestation presents as atypical genitalia; in late gestation as micropenis; in childhood as delayed pubertal development; and in adulthood as decreased sexual function, infertility, and, eventually, loss of secondary sex characteristics. The examination of the man should include the following components. (See "Clinical features and diagnosis of male hypogonadism".)

Skin – Men with iron overload syndromes as the cause of infertility may have diffuse or patchy hyperpigmentation. Men with Cushing's syndrome may have thin skin, ecchymoses, and/or broad purple striae. Loss of pubic, axillary, and facial hair, decreased oiliness of the skin, and fine facial wrinkling suggest longstanding testosterone deficiency.

External genitalia – The genital examination is the most important aspect of physical examination in the assessment of an infertile man. Several abnormalities that affect fertility can be recognized by examination of the external genitalia:

Incomplete sexual development can be recognized by examining the phallus and testes and finding small testes and other findings of incomplete pubertal development (Tanner stage less than 5). (See "Normal puberty".)

Diseases that affect sperm maturation and transport can be detected by examination of the scrotum for absence of the vasa, epididymal thickening, and large varicoceles. (See "Nonacute scrotal conditions in adults", section on 'Varicocele' and "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Infertility'.)

Approximately 90 percent of testicular volume consists of seminiferous tubules that make sperm, and subnormal testicular volumes correlate with decreased sperm production and sperm concentrations in the ejaculate. Decreased volume of the seminiferous tubules can be detected by measuring testicular size by Prader orchidometer or calipers. The Prader orchidometer consists of a series of plastic ellipsoids with a volume from 1 to 35 cc (picture 1). In an adult man, a testicular volume less than 15 cc (as measured by Prader orchidometry) or a testicular length (measured on the longest axis) less than 3.6 cm is considered small.

Prader orchidometry is adequate for assessment of testicular volumes in the evaluation of the infertile man [7]. Prader orchidometry has been reported to estimate greater (approximately 25 to 30 percent) testicular volumes than those by ultrasound, and the overestimation in size is greater with smaller testicles [8-10]. However, these studies showed a high correlation between volumes measured by Prader orchidometry and ultrasound. A systematic review confirmed that ultrasound is more accurate than the Prader orchidometer to assess testicular volume, but that measurements by both methods are closely related.

Semen analysis — Semen analysis is the key laboratory assessment of the male partner of an infertile couple. The standard semen analysis consists of the following:

Semen volume and pH

Microscopy for:

Sperm concentration, count, motility, and morphology

Debris and agglutination

Leukocyte count

Immature germ cells

The semen sample should be collected after two to seven days of ejaculatory abstinence. If possible, the patient should collect the sample by masturbation at the doctor's office. If not possible, then the sample may be collected at home and delivered to the laboratory within an hour of collection.

The semen analysis should be performed using standardized methods, preferably those described in the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen [11]. In addition, the laboratory should employ internal quality control measures and participate in external quality control programs available from national andrology, clinical chemistry, and pathology societies [11,12]. A single seminal fluid analysis suffices for the initial evaluation of male infertility, but one to two additional fluid analyses should be performed if any abnormalities are found [5].

Reference limits — The WHO has published lower reference limits for semen analyses [13]. The following parameters represent the generally accepted 5th percentile (lower reference limits and 95% CIs in parentheses), derived from a study of over 1900 men whose partners had a time to pregnancy of ≤12 months [13]:

Volume – 1.5 mL (95% CI 1.4-1.7)

Sperm concentration – 15 million spermatozoa/mL (95% CI 12-16)

Total sperm number – 39 million spermatozoa per ejaculate (95% CI 33-46)

Morphology – 4 percent normal forms (95% CI 3-4), using "strict" Tygerberg method [11]

Vitality – 58 percent live (95% CI 55-63)

Progressive motility – 32 percent (95% CI 31-34)

Total (progressive and nonprogressive) motility – 40 percent (95% CI 38-42)

Additional evaluation — After the initial evaluation (history, physical examination, and semen analysis), men with infertility should undergo the following evaluation:

Men with a normal semen analysis — Male partners in an infertile couple may have idiopathic male infertility. Other possibilities include infertility of the female partner or a couples' infertility factor (including insufficient frequency or duration of unprotected vaginal intercourse that should occur at least one to two times weekly for optimal conception rates). After complete evaluation of the female partner and treatment of reversible causes of female infertility, the couple should consider referral to a specialist in ART, such as in vitro fertilization (IVF).

Men with an abnormal semen analysis — Most infertile men with abnormal semen analyses have abnormalities in sperm concentrations, morphology, and motility.

Normal sperm concentration, abnormal morphology and/or motility — In an infertile couple with a male partner who has a normal sperm concentration but abnormal sperm morphology and/or motility, referral to a specialist in ART, such as intracytoplasmic sperm injection (ICSI), might be useful. (See "Treatments for male infertility", section on 'IVF with ICSI'.)

Sperm concentration <5 million/mL — Because Klinefelter syndrome is common in men presenting with infertility and sperm concentrations <5 million/mL, serum total testosterone (on a blood sample obtained between 8 and 10 AM), serum follicle-stimulating hormone (FSH), and luteinizing hormone (LH) measurements should be performed in these men [5,14]. The results of the endocrine testing and details from the history and physical examination can help identify the cause of the infertility.

Severe oligozoospermia or azoospermia — Men with azoospermia or severe oligozoospermia also need endocrine testing; further evaluation also depends upon the results (see 'Endocrine testing' below). In addition to undergoing endocrine testing, men with severe oligozoospermia or azoospermia require genetic testing. (See 'Genetic tests' below.)

Some men may require transrectal ultrasound for evaluation of obstructive azoospermia (those who have normal endocrine testing, normal testicular volume, palpable vasa deferentia on examination, and azoospermia). (See 'Scrotal and transrectal ultrasound' below.)

Endocrine testing — The endocrine assessment of an infertile man with a low sperm concentration (<5 million/mL) includes measurements of serum total testosterone, LH, and FSH and other tests as clinically indicated [15,16]. Serum total testosterone should be measured on a blood sample obtained between 8 and 10 AM. The measurement should be repeated in men with borderline values (see "Clinical features and diagnosis of male hypogonadism", section on 'Serum total testosterone'). The following combinations of serum testosterone, LH, and FSH suggest the following diagnoses:

Low testosterone, and high FSH and LH – Primary (hypergonadotropic) hypogonadism (affecting both spermatogenesis and Leydig cell function). These men should have a karyotype performed. Some experts do not recommend a karyotype if there is another clearly identified cause of primary hypogonadism. However, Klinefelter syndrome is common enough in infertile men with primary hypogonadism that karyotyping is reasonable even in the man with another cause of primary hypogonadism [14,17]. (See 'Genetic tests' below and "Principles of magnetic resonance imaging".)

Normal testosterone and LH and high FSH – Primary (hypergonadotropic) hypogonadism (seminiferous tubule damage without Leydig cell dysfunction). These men have isolated defects in spermatogenesis and intact sex hormone steroidogenesis with normal circulating testosterone concentrations. (See "Causes of male infertility", section on 'Primary testicular defects in spermatogenesis'.)

Low testosterone, but FSH and LH not elevated (normal or low) – Secondary (hypogonadotropic) hypogonadism. Serum prolactin should be measured in men with a low serum testosterone concentration, and normal to low serum LH and iron overload syndromes should be excluded with iron studies. Men with low serum testosterone and low gonadotropin concentrations should be evaluated for a sellar mass, other causes of secondary hypogonadism, and other pituitary hormone deficiencies (secondary hypothyroidism and hypoadrenalism). (See "Clinical features and diagnosis of male hypogonadism", section on 'Secondary hypogonadism'.)

High testosterone and LH, but normal FSH – Partial androgen resistance. (See "Pathogenesis and clinical features of disorders of androgen action".)

Normal testosterone, LH, and FSH – Further evaluation depends upon findings on semen analysis (eg, azoospermia, oligozoospermia, asthenozoospermia, or teratozoospermia). (See "Treatments for male infertility", section on 'Normal serum T, normal LH and FSH'.)

Men with azoospermia and normal endocrine testing should be evaluated for ejaculatory duct obstruction. (See "Treatments for male infertility", section on 'Obstruction of epididymis or ejaculatory duct'.)

Most infertile men who have normal serum testosterone concentrations, normal serum gonadotropin concentrations, and a primary defect in spermatogenesis have sperm in the ejaculate, but the numbers of sperm with normal motility and/or normal morphology are low. Clinicians should treat infertile men with oligozoospermia and normal serum hormones similarly to men with idiopathic infertility (ie, men with normal semen analyses and normal serum hormones). There is no clearly effective medical therapy for these men. Strategies include continuation of attempts at natural conception or ART. (See "Treatments for male infertility", section on 'Assisted reproductive technologies'.)

Low sperm count and very low LH in a man who is very muscular – Suspicious for androgen abuse. (See "Use of androgens and other hormones by athletes".)

Scrotal and transrectal ultrasound — Scrotal or testicular ultrasound are useful if a patient has normal testicular volumes, normal serum testosterone, FSH, and LH, and azoospermia because the likely diagnosis is obstructive azoospermia. Scrotal or transrectal ultrasound should be done if the vasa differentia are not palpable on examination; this finding is important to confirm because it is associated with cystic fibrosis. Congenital absence of the vas deferentia may be the only manifestation of cystic fibrosis [16]. Ejaculatory duct obstruction can be diagnosed by a scrotal or transrectal ultrasound showing dilated seminal vesicles [18-21]. Transrectal ultrasound might be modestly more sensitive in detecting obstructive azoospermia [22]. Patients with obstructive azoospermia should be referred to a urologist specialized in infertility for further evaluation and treatment. (See "Treatments for male infertility", section on 'Obstructive azoospermia'.)

Although there is some controversy about the clinical significance of nonpalpable varicoceles in infertile men, it is not necessary to perform scrotal or transrectal ultrasound to detect small varicoceles because palpation is sufficient to detect large varicoceles that might be associated with male infertility [5,7,23].

Magnetic resonance imaging — Magnetic resonance imaging might be slightly more sensitive for detecting partial ejaculatory duct obstruction, but the expense of this imaging modality is not generally justifiable [20,21].

Genetic tests — Karyotyping and testing for Y chromosome microdeletions should be done in infertile men with sperm concentrations <5 million/mL before any ART therapy is performed [5,14]. Klinefelter syndrome is common in these men, and chromosomal translocations occur in up to 15 percent of men with severe oligozoospermia or azoospermia [5,14,24,25]. Men with absence of bilateral vasa differentia should be tested for gene mutations associated with cystic fibrosis (cystic fibrosis transmembrane conductance regulator [CFTR] gene mutations) [5]. ART has made it possible for men with severe oligozoospermia and azoospermia to pursue fertility, but there is a small risk of transferring somatic and sex chromosome abnormalities, microdeletions of the Y chromosome, X chromosome defects, and CFTR gene mutations to the offspring [5,14,17]. (See "Treatments for male infertility", section on 'Retrieval of sperm'.)

SEMEN ANALYSES

Semen analysis interpretation — Most infertile men with abnormal semen analyses have abnormalities in sperm concentration, morphology, and motility.

Low volume

Low semen volume with normal sperm concentration is most likely due to incomplete collection of the ejaculate or partial retrograde ejaculation. The patient should be asked to return for a carefully collected repeat semen sample after emptying the bladder; post-ejaculation urine can be collected to assess whether there is retrograde ejaculation [16].

Low semen volume and low sperm concentration may also be seen in some men with testosterone deficiency.

Endocrine assessment of possible testosterone deficiency is reviewed above. (See 'Endocrine testing' above.)

A low volume with azoospermia (no sperm) or severe oligozoospermia (severely subnormal sperm concentration) suggests genital tract obstruction (eg, congenital absence of the vas deferens and seminal vesicles, or ejaculatory duct obstruction). (See 'Scrotal and transrectal ultrasound' above.)

Congenital absence of vas deferens is suspected by physical examination and confirmed by scrotal or transrectal ultrasound.

Ejaculatory duct obstruction is diagnosed by the finding of dilated seminal vesicles on scrotal or transrectal ultrasonography. (See 'Scrotal and transrectal ultrasound' above.)

Low concentration — The lower reference limit for sperm concentration is 15 million/mL (95% CI 12-16) [13] (see 'Reference limits' above). However, some men with sperm counts considered to be low can be fertile, while others above the lower limit of normal can be subfertile [26-28]. In addition, for the purposes of in vitro fertilization (IVF), 10 million/mL or even less can be satisfactory [11].

Lack of sperm in the ejaculate does not indicate the absence of sperm production; these patients should be evaluated for retrograde ejaculation, congenital absence of the vas deferens, and other causes of obstructive azoospermia. (See "Causes of male infertility", section on 'Sperm transport disorders'.)

If few or no spermatozoa per high-power field are observed, there are special techniques to increase the sensitivity of detecting sperm in the ejaculate [13,29]. Identifying even a few spermatozoa in the ejaculate is useful because it indicates that assisted reproductive technologies (ART) might be effective. (See "Treatments for male infertility", section on 'IVF with ICSI'.)

Abnormal morphology — The criteria for sperm morphology are based on length, width, width ratio, area occupied by the acrosome, and neck and tail defects [13,30,31]. Sperm morphology assessment has modest clinical value [32]. It is useful for detecting selected, very rare genetic causes of male infertility [32]. It has been claimed that morphologic assessment has good predictive value for pregnancy rates after IVF [30,31,33], but these claims are controversial and not well supported by clinical studies [32].

Round cells in the seminal fluid may be leukocytes, immature germ cells, or degenerating epithelial cells [11]. Presence of immature germ cells in the semen usually indicates disorders of spermatogenesis. White blood cells, mainly polymorphonuclear leukocytes, are frequently present in the seminal fluid. Presence of increased white blood cells in the ejaculate may be a marker of genital infection/inflammation and may be associated with poor semen quality because of the release of reactive oxygen species from the leukocytes. The suggested cutoff for the diagnosis of a possible infection is one million leukocytes/mL of ejaculate. However, this cutoff has poor predictive value for bacterial infection [34,35].

Poor motility — In general, motility is not an important factor in independently predicting the probability of natural pregnancy, unless a very high percentage of sperm in ejaculate are immotile [36]. Men with a very high percentage of immotile sperm might still be treatable with intracytoplasmic sperm injection (ICSI) [36]. (See "Treatments for male infertility", section on 'IVF with ICSI'.)

Prediction of fertility — The standard semen analysis provides descriptive data that do not always distinguish fertile from infertile men [36]. In one prospective study of 430 couples, among those with a sperm concentration ≥40 x 106/mL, 65 percent achieved pregnancy compared with 51 percent of those with lower sperm concentrations [37]. In a study of male partners in 765 infertile couples in which the female partners had normal infertility workup and in 696 control fertile couples recruited from prenatal classes, there was extensive overlap between fertile and infertile men in sperm concentration, motility, and morphology [28]. However, men who have a "triple" defect of low sperm concentrations, low percentage of normal morphology, and low percentage of motile sperm have a high probability of infertility [36].

At-home test — At-home testing of sperm quality is commercially available. We do not recommend these at-home tests in the evaluation of male infertility, because these tests do not assess sperm morphology and they have not been carefully studied for reliability [38,39].

Specialized sperm and semen tests — We suggest not doing specialized sperm and semen tests, such as antisperm autoantibodies, seminal fluid fructose, or semen culture.

The presence of agglutination in the initial semen analysis suggests sperm autoantibodies that are present in 4 to 8 percent of infertile men [11]. However, sperm autoantibodies do not appear to cause infertility. (See "Causes of male infertility".)

Sperm biochemistry is frequently described in semen analyses but is rarely useful in clinical practice. The most commonly ordered test is fructose, which is a marker of seminal vesicle function, and seminal fructose might be low in men with ejaculatory duct obstruction [40]. This test is not routinely used.

Semen culture is sometimes performed in men whose semen samples contain inflammatory cells, but semen culture results have not been proven to be useful.

There are numerous other specialized sperm and semen tests (including tests of sperm DNA damage) that are used in some fertility clinics and laboratories, but these tests lack standardization and evidence to support their routine use [36,41,42]. Tests of sperm DNA fragmentation might prove to be useful, but the evidence to support their use is based almost exclusively on retrospective studies, case series, and expert opinion [43].

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Male infertility or hypogonadism".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Male infertility (The Basics)")

Beyond the Basics topics (see "Patient education: Treatment of male infertility (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Initial evaluation

Identify treatable causes The evaluation of male infertility should focus on identifying treatable causes and factors that might affect the outcome of therapy or the health of offspring. (See 'Diagnostic approach' above.)

Female partner The female partner must be evaluated thoroughly before or concurrent with the male partner of an infertile couple. (See 'Initial visit' above.)

Semen analysis Semen analysis is the fundamental investigation for the infertile male and directs the subsequent evaluation. (See 'Semen analysis' above.)

If the initial semen analysis has any abnormality, it should be repeated. If repeated semen analyses demonstrate a sperm concentration less than 5 million spermatozoa/mL, then serum testosterone, serum follicle-stimulating hormone (FSH), and luteinizing hormone (LH) should be measured. (See 'Semen analysis' above.)

Additional evaluation

Scrotal and transrectal ultrasound – Impalpable vasa deferentia on physical examination suggest congenital absence of vasa deferentia. This finding should be confirmed with ultrasound. These patients should be tested for the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations, and, if positive in either the man or the female partner, genetic counseling should be offered before assisted reproductive technology (ART) therapies are performed.

Ejaculatory duct obstruction – If seminal fluid pH and volume are low (<1.5 mL) in a man with azoospermia, normal-sized testes, and normal serum testosterone, FSH, and LH concentrations, retrograde ejaculation or ejaculatory duct obstruction is likely and a postejaculatory urine sample analysis and transrectal ultrasound imaging should be performed. (See 'Scrotal and transrectal ultrasound' above.)

Genetic testing – Karyotyping and testing for Y chromosome microdeletions should be offered to all infertile men with sperm concentrations <5 million/mL before any ART therapy is performed. (See 'Genetic tests' above.)

ACKNOWLEDGMENTS — The UpToDate editorial staff acknowledges Ronald Swerdloff, MD, Christina Wang, MD, and Stephanie Page, MD, who contributed to earlier versions of this topic review.

  1. Practice Committee of tAmerican Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008; 90:S60.
  2. Evers JL. Female subfertility. Lancet 2002; 360:151.
  3. Annual Capri Workshop Group. Towards a more pragmatic and wiser approach to infertility care. Hum Reprod 2019; 34:1165.
  4. Winters BR, Walsh TJ. The epidemiology of male infertility. Urol Clin North Am 2014; 41:195.
  5. Barratt CLR, Björndahl L, De Jonge CJ, et al. The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities. Hum Reprod Update 2017; 23:660.
  6. Kruger TF, Acosta AA, Simmons KF, et al. Predictive value of abnormal sperm morphology in in vitro fertilization. Fertil Steril 1988; 49:112.
  7. Lotti F, Maggi M. Ultrasound of the male genital tract in relation to male reproductive health. Hum Reprod Update 2015; 21:56.
  8. Sakamoto H, Saito K, Oohta M, et al. Testicular volume measurement: comparison of ultrasonography, orchidometry, and water displacement. Urology 2007; 69:152.
  9. Diamond DA, Paltiel HJ, DiCanzio J, et al. Comparative assessment of pediatric testicular volume: orchidometer versus ultrasound. J Urol 2000; 164:1111.
  10. Mbaeri TU, Orakwe JC, Nwofor AM, et al. Accuracy of Prader orchidometer in measuring testicular volume. Niger J Clin Pract 2013; 16:348.
  11. World Health Organization Department of Reproductive Health and Research. World Health Organization Laboratory Manual for the Examination and Processing of Human Semen, 5th ed, World Health Organization, Geneva, Switzerland 2010.
  12. McLachlan RI, Baker HW, Clarke GN, et al. Semen analysis: its place in modern reproductive medical practice. Pathology 2003; 35:25.
  13. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010; 16:231.
  14. McLachlan RI. Approach to the patient with oligozoospermia. J Clin Endocrinol Metab 2013; 98:873.
  15. Sokol RZ. Endocrinology of male infertility: evaluation and treatment. Semin Reprod Med 2009; 27:149.
  16. Anawalt BD. Approach to male infertility and induction of spermatogenesis. J Clin Endocrinol Metab 2013; 98:3532.
  17. Hofherr SE, Wiktor AE, Kipp BR, et al. Clinical diagnostic testing for the cytogenetic and molecular causes of male infertility: the Mayo Clinic experience. J Assist Reprod Genet 2011; 28:1091.
  18. Meacham RB, Hellerstein DK, Lipshultz LI. Evaluation and treatment of ejaculatory duct obstruction in the infertile male. Fertil Steril 1993; 59:393.
  19. Jarow JP. Transrectal ultrasonography in the diagnosis and management of ejaculatory duct obstruction. J Androl 1996; 17:467.
  20. Jurewicz M, Gilbert BR. Imaging and angiography in male factor infertility. Fertil Steril 2016; 105:1432.
  21. Huang IS, Wren J, Bennett NE, Brannigan RE. Clinical Consultation Guide on Imaging in Male Infertility and Sexual dysfunction. Eur Urol Focus 2018; 4:338.
  22. Abdulwahed SR, Mohamed EE, Taha EA, et al. Sensitivity and specificity of ultrasonography in predicting etiology of azoospermia. Urology 2013; 81:967.
  23. Kroese AC, de Lange NM, Collins J, Evers JL. Surgery or embolization for varicoceles in subfertile men. Cochrane Database Syst Rev 2012; 10:CD000479.
  24. McLachlan RI, O'Bryan MK. Clinical Review#: State of the art for genetic testing of infertile men. J Clin Endocrinol Metab 2010; 95:1013.
  25. Martin RH. Cytogenetic determinants of male fertility. Hum Reprod Update 2008; 14:379.
  26. Jørgensen N, Andersen AG, Eustache F, et al. Regional differences in semen quality in Europe. Hum Reprod 2001; 16:1012.
  27. Swan SH, Brazil C, Drobnis EZ, et al. Geographic differences in semen quality of fertile U.S. males. Environ Health Perspect 2003; 111:414.
  28. Guzick DS, Overstreet JW, Factor-Litvak P, et al. Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med 2001; 345:1388.
  29. Cooper TG, Hellenkemper B, Jonckheere J, et al. Azoospermia: virtual reality or possible to quantify? J Androl 2006; 27:483.
  30. Menkveld R, Stander FS, Kotze TJ, et al. The evaluation of morphological characteristics of human spermatozoa according to stricter criteria. Hum Reprod 1990; 5:586.
  31. Kruger TF, du Toit TC, Franken DR, et al. Sperm morphology: assessing the agreement between the manual method (strict criteria) and the sperm morphology analyzer IVOS. Fertil Steril 1995; 63:134.
  32. Gatimel N, Moreau J, Parinaud J, Léandri RD. Sperm morphology: assessment, pathophysiology, clinical relevance, and state of the art in 2017. Andrology 2017; 5:845.
  33. Kruger TF, Menkveld R, Stander FS, et al. Sperm morphologic features as a prognostic factor in in vitro fertilization. Fertil Steril 1986; 46:1118.
  34. Wolff H. The biologic significance of white blood cells in semen. Fertil Steril 1995; 63:1143.
  35. Lackner J, Schatzl G, Horvath S, et al. Value of counting white blood cells (WBC) in semen samples to predict the presence of bacteria. Eur Urol 2006; 49:148.
  36. Wang C, Swerdloff RS. Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests. Fertil Steril 2014; 102:1502.
  37. Bonde JP, Ernst E, Jensen TK, et al. Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners. Lancet 1998; 352:1172.
  38. Björndahl L, Kirkman-Brown J, Hart G, et al. Development of a novel home sperm test. Hum Reprod 2006; 21:145.
  39. Klotz KL, Coppola MA, Labrecque M, et al. Clinical and consumer trial performance of a sensitive immunodiagnostic home test that qualitatively detects low concentrations of sperm following vasectomy. J Urol 2008; 180:2569.
  40. Dieudonné O, Godin PA, Van-Langendonckt A, et al. Biochemical analysis of the sperm and infertility. Clin Chem Lab Med 2001; 39:455.
  41. Zini A, Bach PV, Al-Malki AH, Schlegel PN. Use of testicular sperm for ICSI in oligozoospermic couples: how far should we go? Hum Reprod 2017; 32:7.
  42. Tomlinson M, Lewis S, Morroll D, British Fertility Society. Sperm quality and its relationship to natural and assisted conception: British Fertility Society guidelines for practice. Hum Fertil (Camb) 2013; 16:175.
  43. Dutta S, Henkel R, Agarwal A. Comparative analysis of tests used to assess sperm chromatin integrity and DNA fragmentation. Andrologia 2021; 53:e13718.
Topic 7453 Version 22.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟